预约演示
更新于：2025-09-04
Miglitol
米格列醇
更新于：2025-09-04
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 荷兰 (1996-07-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H17NO5 |
InChIKeyIBAQFPQHRJAVAV-ULAWRXDQSA-N |
CAS号72432-03-2 |
关联
47
项与 米格列醇 相关的临床试验CTR20250848
北京北陆药业股份有限公司研制的米格列醇片与原研参比制剂在中国健康受试者中进行的单中心、随机、开放、两制剂、空腹、单次给药、两周期、双交叉设计的生物等效性研究
CTR20250552
米格列醇片(50mg)在健康受试者中的单次给药、随机、开放、两制剂、两序列、两周期、双交叉、空腹状态下的PK和PD生物等效性研究
CTR20250214
观察持证商为三和化学研究所株式会社的米格列醇片（规格：25 mg，商品名：SEIBULE®）在中国健康受试者中进行的单中心、开放、单序列、空腹、三周期、单次给药设计的剂量探索试验
100 项与 米格列醇 相关的临床结果
登录后查看更多信息
100 项与 米格列醇 相关的转化医学
登录后查看更多信息
100 项与 米格列醇 相关的专利（医药）
登录后查看更多信息
637
项与 米格列醇 相关的文献（医药）2025-12-31JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
A stable GH31 α-glucosidase as a model system for the study of mutations leading to human glycogen storage disease type II
Article
作者: Moracci, Marco ; Strazzulli, Andrea ; Paragliola, Francesca Maria Pia ; Iacono, Roberta
GH31 glycosidases are widespread across organisms, but remarkably, less than 1% of them have been biochemically characterised to date. Among them, human lysosomal acid α-glucosidase (GAA) stands out due to its link to Pompe disease, a rare lysosomal storage disorder caused by its deficiency. This disease results in glycogen accumulation, severe cellular damage, motor impairment, and premature death. Structural and functional studies of GAA mutants are challenging due to their instability and lack of activity, hindering their expression and purification. The GH31 enzyme MalA from a hyperthermophilic archaeon is explored here as a stable homolog of GAA. MalA is highly expressible, easy to purify, and structurally characterised. The R400H mutant in MalA, corresponding to the pathogenic GAA R600H mutation, revealed here a 1200-fold drop in specificity constant and >8 °C reduction in thermal stability. We propose MalA's as a robust model for studying GAA mutations and developing therapeutic chaperones.
2025-09-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
The synergistic inhibition of isoginkgetin with miglitol and acarbose on α-glucosidase: Dynamics enzyme changes tracking
Article
作者: Li, Yuan ; Zhang, Xue ; Cui, Jingjing ; Lian, Di ; Li, Li ; Du, Yutong ; Qu, Zihan
Isoginkgetin is an edible biflavone from ginkgo biloba leaves with many bioactivities. In this work, the inhibition and synergistic effect of isoginkgetin with miglitol or acarbose on saccharomyces cerevisiae α-glucosidase (α-SCG) were tracked via various spectroscopic techniques and computer simulations. Compared with miglitol or acarbose, isoginkgetin displayed more remarkable inhibition effect on α-SCG. In the presence of isoginkgetin, miglitol and acarbose exhibited stronger inhibitory effect on α-SCG than miglitol and acarbose alone. Isoginkgetin exerted the synergistic inhibitory effect by significantly increasing the binding affinity of acarbose or miglitol with α-SCG, leading to larger structural changes in α-SCG. The best binding mode, the stability of the formed complex, and the contribution of key amino acids to the binding were deeply analyzed via dynamics simulation. Isoginkgetin can be used as a strong inhibitor of α-SCG and synergistic inhibitor of miglitol or acarbose.
2025-08-01BIOORGANIC CHEMISTRY
Dual α-amylase and α-glucosidase inhibitors: recent progress from natural and synthetic resources
Review
作者: Jha, Ritesh ; Mehan, Sidharth ; Goyal, Kamya ; Singh, Gurpreet
Diabetes mellitus (DM) is a chronic metabolic disorder characterised by elevated blood glucose levels resulting from insufficient insulin production or insulin resistance. Its global prevalence has surged, particularly in low- and middle-income countries, with over 830 million affected. In recent years, dual inhibition of α-amylase and α-glucosidase, the enzymes involved in the metabolism of complex polysaccharides, has gained visibility in anti-diabetic medication research. The inhibition of these enzymes is responsible for reducing postprandial hyperglycemia. FDA-approved drugs, acarbose, voglibose, and miglitol, are effective but have serious side effects. Many research papers from various research groups have appeared in different databases, from natural to synthetic resources, describing the dual inhibition of α-amylase and α-glucosidase. However, none of the molecules have advanced to clinical development. The current review focuses on compiling an exhaustive report of novel molecules derived from synthetic and natural resources that act as dual α-amylase and α-glucosidase inhibitors. The review also highlights their biological activity, selectivity, structure-activity relationship, molecular docking, and mechanistic studies. A special emphasis on drug-designing strategies has also been given in the manuscript. The comprehensive compilation of research work in the field will provide an inevitable scope for designing and developing novel adenosine inhibitors with improved selectivity and efficacy.
100 项与 米格列醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 日本 | 2005-10-11 | |
| 2型糖尿病 | 荷兰 | - | 1996-07-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 1型糖尿病 | 临床3期 | 日本 | 2005-09-21 | |
| 肥胖 | 临床2期 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 41 | 壓製網鑰選淵醖構鬱網(醖襯鹽艱顧願膚襯鬱網) = 艱獵觸顧繭遞選顧膚鹹 遞醖餘餘衊齋憲鬱鏇遞 (鬱觸選鏇蓋簾簾壓齋齋, 0.11) 更多 | 积极 | 2013-09-24 | |||
Sitagliptin | 壓製網鑰選淵醖構鬱網(醖襯鹽艱顧願膚襯鬱網) = 艱淵窪膚鹽網蓋窪網襯 遞醖餘餘衊齋憲鬱鏇遞 (鬱觸選鏇蓋簾簾壓齋齋, 0.17) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用